Abstract As a strategy to improve the therapeutic success of chimeric antigen receptor T cells (CART) directed against solid tumors. we here test the combinatorial use of CART and IMSA101. a newly developed stimulator of interferon genes (STING) agonist. In two syngeneic tumor models. https://www.markymarkscott.com/product-category/glycerine-origina/